Epidemiology and risk factors for (Tardive) Dyskinesia

International Review of Neurobiology

Volumn 98, Issue , 2011, Pages 211-230

  Tenback, Diederik E ^a,b   van Harten, Peter N ^a,c  

^a GGz Centraal Psychiatric Center   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Epidemiology; Mental disorders; Movement disorders; Risk factors; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; HALOPERIDOL; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT; RISPERIDONE;

AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; BOOK; COMORBIDITY; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DISEASE ASSOCIATION; DRUG SAFETY; DYSKINESIA; GENE; HUMAN; LONG TERM CARE; NEUROPATHOLOGY; OXIDATIVE STRESS; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

EID: 80052541076     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381328-2.00009-2     Document Type: Chapter

References (88)

1. Abdolmaleky H.M., Thiagalingam S., et al. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am. J. Pharmacogenomics 2005, 5(3):149-160.
2. Ascher-Svanum H., Zhu B., et al. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J. Clin. Psychiatry 2008, 69(10):1580-1588.
3. Bakker P.R., van Harten P.N., et al. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol. Psychiatry 2008, 13(5):544-556.
4. Barnes T.R. The Barnes Akathisia Rating Scale-revisited. J. Psychopharmacol. 2003, 17(4):365-370.
5. Barnes T.R., Kidger T., et al. Tardive dyskinesia: a 3-year follow-up study. Psychol. Med. 1983, 13(1):71-81.
6. Bergen J.A., Carter N.B., et al. AIMS ratings-repeatability. Br. J. Psychiatry 1988, 152:670-673.
7. Bergen J.A., Eyland E.A., et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br. J. Psychiatry 1989, 154:523-528.
8. Bergen J.A., Griffiths D.A., et al. Tardive dyskinesia: fluctuating patient or fluctuating rater. Br. J. Psychiatry 1984, 144:498-502.
9. Boks M.P., Russo S., et al. The specificity of neurological signs in schizophrenia: a review. Schizophr. Res. 2000, 43(2-3):109-116.
10. Burke R.E., Fahn S., et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982, 32(12):1335-1346.
11. Burke R.E., Kang U.J. Tardive dystonia: clinical aspects and treatment. Adv. Neurol. 1988, 49:199-210.
12. Cacabelos R., Martinez-Bouza R. Genomics and Pharmacogenomics of Schizophrenia. CNS Neurosci. Ther. 2010.
13. Cannon M., Caspi A., et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch. Gen. Psychiatry 2002, 59(5):449-456.
14. Caroff S.N., Davis V.G., et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J. Clin. Psychiatry 2011, 72(3):295-303.
15. Casey D.E. Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry 2004, 65(Suppl 9):25-28.
16. Chakos M.H., Alvir J.M., et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch. Gen. Psychiatry 1996, 53(4):313-319.
17. Chatterjee A., Chakos M., et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry 1995, 152(12):1724-1729.
18. Chouinard G., Annable L., et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 1988, 8(4 Suppl):21S-26S.
19. Chouinard G., Margolese H.C. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr. Res. 2005, 76(2-3):247-265.
20. Correll C.U., Kane J.M. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J. Child Adolesc. Psychopharmacol. 2007, 17(5):647-656.
21. Correll C.U., Leucht S., et al. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 2004, 161(3):414-425.
22. Correll C.U., Rummel-Kluge C., et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009, 35(2):443-457.
23. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr. Opin. Psychiatry 2008, 21(2):151-156.
24. Cortese L., Caligiuri M.P., et al. Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients. Schizophr. Res. 2005, 75(1):65-75.
25. Dean C.E., Russell J.M., et al. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements?. J. Clin. Psychopharmacol. 2004, 24(3):298-304.
26. Dragt S., Nieman D.H., et al. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr. Res. 2011, 125(1):69-76.
27. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, DSM-IV, A. P. A. T. F. O., American Psychiatric Association, Washington, DC.
28. Ellingrod V.L., Schultz S.K., et al. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002, 22(11):1416-1419.
29. Emsley R., Turner H.J., et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J. Clin. Psychiatry 2004, 65(5):696-701.
30. Emsley R., Turner H.J., et al. Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates. Schizophr. Res. 2005, 75(1):35-44.
31. Erlenmeyer-Kimling L., Rock D., et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am. J. Psychiatry 2000, 157(9):1416-1422.
32. Faurbye A., Rasch P.J., et al. Neurological Symptoms in Pharmacotherapy of Psychoses. Acta Psychiatr. Scand. 1964, 40:10-27.
33. Fenton W.S. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry 2000, 61(Suppl 4):10-14.
34. Fernandez H.H., Krupp B., et al. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001, 56(6):805-807.
35. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160(4):636-645.
36. Guy W.A. Abnormal Involuntary Movement Scale (AIMS) 1976, U. S. Department of Health Education and Welfare, Washington, DC.
37. Guy, W. A. (1976). CDEU Assessment Manual for Psychopharmacology -Revised. (DHEW Publ No ADM 76-338). U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH, Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville.
38. Hirvonen J., van Erp T.G., et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch. Gen. Psychiatry 2005, 62(4):371-378.
39. Hori H., Ohmori O., et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23(2):170-177.
40. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia bulletin 2009, 35(3):549-562.
41. Jeste D.V., Caligiuri M.P., et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch. Gen. Psychiatry 1995, 52(9):756-765.
42. Jeste D.V., Okamoto A., et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J. Psychiatry 2000, 157(7):1150-1155.
43. Jones P., Rodgers B., et al. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 1994, 344(8934):1398-1402.
44. Kane J.M., Fleischhacker W.W., et al. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 2009, 70(5):627-643.
45. Kane J.M., Woerner M., et al. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol. Bull. 1984, 20(3):387-389.
46. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 2001, 158(3):360-369.
47. Koning J.P. Movement Disorders in Schizophrenia and their Siblings 2011, University of Maastricht, MD.
48. Koning J.P., Tenback D.E., et al. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr. Bull. 2008, 36(4):723-731.
49. Koning J.P., Tenback D.E., et al. Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr. Bull. 2010, 36(4):723-731.
50. Koning J.P., Tenback D.E., et al. Movement disorders in nonpsychotic siblings of patients with non-affective psychosis. Psychiatr. Res. 2011, 188(1):133-137.
51. Kraepelin E Dementia Praecox and Paraphrenia 1919, Livingstone, Edinburgh.
52. Margolese H.C., Chouinard G., et al. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can. J. Psychiatry 2005, 50(9):541-547.
53. McCreadie R.G., Ohaeri J.U. Movement disorder in never and minimally treated Nigerian schizophrenic patients. Br. J. Psychiatry 1994, 164(2):184-189.
54. McCreadie R.G., Thara R., et al. Abnormal movements in never-medicated Indian patients with schizophrenia. Br. J. Psychiatry 1996, 168(2):221-226.
55. McCreadie R.G., Thara R., et al. Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. Br. J. Psychiatry 2003, 183:45-49.
56. Miller D.D., Eudicone J.M., et al. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J. Clin. Psychiatry 2007, 68(12):1901-1906.
57. Mittal V.A., Neumann C., et al. Longitudinal progression of movement abnormalities in relation to psychotic symptoms in adolescents at high risk of schizophrenia. Arch. Gen. Psychiatry 2008, 65(2):165-171.
58. Morgenstern H., Glazer W.M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry 1993, 50(9):723-733.
59. Murray R.M., Van Os J. Predictors of outcome in schizophrenia. J. Clin. Psychopharmacol. 1998, 18(2 Suppl 1):2S-4S.
60. Oosthuizen P.P., Emsley R.A., et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J. Clin. Psychiatry 2003, 64(9):1075-1080.
61. Owens D.G., Johnstone E.C., et al. Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch. Gen. Psychiatry 1982, 39(4):452-461.
62. Pappa S., Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol. Med. 2009, 39(7):1065-1076.
63. Patsopoulos N.A., Ntzani E.E., et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet. Genomics 2005, 15(3):151-158.
64. Peralta V., Campos M.S., et al. Motor behavior abnormalities in drug-naive patients with schizophrenia spectrum disorders. Mov. Disord. 2010, 25(8):1068-1076.
65. Schooler N., Rabinowitz J., et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 2005, 162(5):947-953.
66. Silvestri S., Seeman M.V., et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000, 152(2):174-180.
67. Strous R.D., Alvir J.M., et al. Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects. Schizophr. Bull. 2004, 30(2):265-278.
68. Tenback D.E., van Harten P.N., et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J. Clin. Psychiatry 2005, 66(9):1130-1133.
69. Tenback D.E., van Harten P.N., et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am. J. Psychiatry 2006 a, 163(8):1438-1440.
70. Tenback D.E., van Harten P.N., et al. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006 b, 31(8):1832-1837.
71. Tenback D.E., van Harten P.N., et al. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr. Psychiatry 2007, 48(5):436-440.
72. Tenback D.E., van Harten P.N., et al. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov. Disord. 2009, 24(16):2309-2315.
73. Tenback D.E., van Harten P.N., et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J. Psychopharmacol. 2010, 24(7):1031-1035.
74. Tenback, D. E., and van Harten, P. N. (2011). Movement disorders Schizofrenia Manual (W. Cahn. Utrecht, De Tijdstroom).
75. Thelma B., Srivastava V., et al. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008, 9(9):1285-1306.
76. Tiwari A.K., Deshpande S.N., et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr. Res. 2005, 75(1):21-26.
77. Tiwari A.K., Deshpande S.N., et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 2005, 5(1):60-69.
78. van Harten P.N., Hoek H.W., et al. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II. Schizophr. Res. 1997, 26(2-3):235-242.
79. van Harten P.N., Hoek H.W., et al. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao extrapyramidal syndromes study V. J. Clin. Psychiatry 2006, 67(12):1920-1927.
80. van Harten P.N., Tenback D.E. Movement disorders should be a criterion for schizophrenia in DSM-V. Psychol. Med. 2009, 39(10):1754-1755. (author reply 1755-1756).
81. van Os J., Fahy T., et al. Tardive dyskinesia: who is at risk?. Acta Psychiatr. Scand. 1997, 96(3):206-216.
82. van Rossum I., Tenback D., et al. Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting. BMC Psychiatry 2009, 9:16.
83. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374(9690):635-645.
84. Zai C.C., Tiwari A.K., et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010 a, 34(1):50-56.
85. Zai C.C., Tiwari A.K., et al. The catechol-O-methyl-transferase gene in tardive dyskinesia. World J. Biol. Psychiatry 2010 b, 11(6):803-812.
86. Zhang J.P., Lencz T., et al. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am. J. Psychiatry 2010, 167(7):763-772.
87. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 2009, 48(11):689-723.
88. Zhou S.F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin. Pharmacokinet. 2009, 48(12):761-804.